Melanotan II: What the Safety Literature Actually Says
Melanotan II is a non-selective melanocortin-receptor agonist that has been on the MHRA and FDA warning radars for over a decade. The pharmacology is interesting; the safety literature — including dermatological case reports — is the part most marketing omits.
melanotan II is a non-selective agonist across multiple melanocortin receptors.
the UK Medicines and Healthcare products Regulatory Agency has issued repeated public warnings against melanotan II since 2008.
the dermatology literature contains case reports of changing nevi, melanoma diagnoses and other dermatological events in melanotan II users.
no regulator (EMA, MHRA, FDA, TGA) has approved melanotan II for any indication.
Melanotan II is a synthetic cyclic peptide agonist at multiple melanocortin receptors. Originally developed at the University of Arizona as a photoprotection candidate, it has been marketed online for tanning purposes. The regulatory status is unambiguous: not approved by any major regulator, with active public warnings from MHRA, FDA and others. The dermatology and adverse-event literature includes case reports of new and changing nevi, melanoma diagnoses, priapism and gastrointestinal effects.
Pharmacology that does what it says — and a safety literature with case reports the marketing does not mention. This is a peptide where regulatory absence is itself information.
What it is
Melanotan II is a synthetic cyclic heptapeptide non-selective melanocortin receptor agonist. It was developed in the 1980s at the University of Arizona by the Hadley/Hruby group, initially as a photoprotection candidate (the idea: stimulate melanogenesis pharmacologically to reduce UV-related skin damage).
Mechanistically it activates multiple melanocortin receptors: MC1 (melanocytes, pigmentation), MC3 and MC4 (CNS appetite and sexual response), MC5 (exocrine glands). The non-selectivity is the source of much of the side-effect profile.
It is not approved as a medicine by any major regulator. Afamelanotide (Scenesse) — a different, more selective molecule — has approval for erythropoietic protoporphyria; melanotan II does not.
Pharmacology
| Layer | What the research describes |
|---|---|
| MC1 | Stimulates melanogenesis; underlies the tanning effect. |
| MC3 / MC4 | CNS effects: appetite suppression, sexual-response stimulation, nausea. |
| MC5 | Exocrine effects; possible role in some side effects. |
| Non-selective profile | Activates multiple receptors simultaneously; the side-effect profile reflects this. |
| Half-life | Substantially longer than endogenous alpha-MSH; effects are prolonged. |
The non-selective receptor profile is the source of both the wide effect range and the wide side-effect range.
What the safety literature shows
Dermatology
Case reports of new naevi, changes to existing naevi, atypical melanocytic lesions and melanoma diagnoses in melanotan II users. Mechanistic plausibility: prolonged melanocyte stimulation in untested populations.
Sexual and GI
Priapism (sustained painful erection), severe nausea and other GI effects are documented in case reports and adverse-event databases.
Regulatory warnings
MHRA (UK) has issued repeated warnings since 2008; FDA, TGA (Australia), and other regulators have warned against unregulated melanotan II.
The dermatology literature is the most important read. Melanotan II's mechanism is exactly what produces pigment — and the case reports of changing pigmented lesions are mechanistically coherent, not coincidental.
The regulatory pattern — repeated warnings from multiple agencies over more than a decade — is unusual and signals something specific. Drugs with favourable risk-benefit usually navigate to some form of approval; melanotan II has not.
What we know, what's still open
- Pharmacology: Well-characterised non-selective melanocortin agonism.
- Tanning effect: Real and reproducible at mechanism level.
- Adverse-event case reports: Documented across dermatology, sexual function and GI literature.
- Regulatory warnings: Multiple agencies, multiple decades, no approvals.
- Long-term safety: Inadequately characterised in any rigorous human population study.
Frequently asked
Is it the same as afamelanotide?
No. Afamelanotide (Scenesse) is a different, more selective molecule with regulatory approval for erythropoietic protoporphyria. Melanotan II is unapproved.
Is the melanoma risk proven?
Case reports establish association and mechanistic plausibility; large epidemiological causality data are absent. The honest position is documented mechanistic risk with clinical case-report evidence.
Is it legal to possess?
Possession is generally not criminalised in most jurisdictions; sale as a medicine is illegal in most without authorisation. See our EU peptide legality reference.
Why is it still marketed?
Online marketing in unregulated channels persists despite agency warnings. The marketing is not the same as regulatory or clinical endorsement.
Where to read further
- • MHRA public warnings on melanotan II (multiple years).
- • Cardones AR, Grichnik JM. Alpha-MSH peptides and melanocytic lesions. JAMA Dermatol.
- • Hadley ME, Dorr RT. Melanocortin peptide therapeutics. Peptides 2006.